Copy Link Print Information

Vistusertib

(Synonyms: AZD2014)
31 Cited Publications
Customer Review

Based on 31 publication(s) in Google Scholar

Vistusertib (AZD2014) is an ATP competitive mTOR inhibitor with an IC50 of 2.81 nM. AZD2014 inhibits both mTORC1 and mTORC2 complexes.

For research use only. We do not sell to patients.

  • Purity: 99.70%
  • CAS No.: 1009298-59-2
  • Formula: C25H30N6O3
  • Molecular Weight:462.54
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 1 year , -20°C, 6 months
  • Vistusertib Chemical Structure
    Vistusertib Chemical Structure
  • Experimental Validation Results for Vistusertib
  • Experimental Validation Results for Vistusertib
  • Experimental Validation Results for Vistusertib
  • Experimental Validation Results for Vistusertib
  • Experimental Validation Results for Vistusertib
CAS No.: 1009298-59-2
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Vistusertib:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Protocol
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Vistusertib

More
Customer Validation & Images
WB
  • WB
  • WB
  • WB
  • WB
  • WB

All mTOR Isoforms

More
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Vistusertib Chemical Structure
    Vistusertib Chemical Structure
    1/16
  • 1/16

    Vistusertib purchased from MedChemExpress. Usage Cited in: Mol Cancer Res. 2019 Jan;17(1):42-53. [Abstract]

    Customer Validation
     Combination of RAD001 with AZD2281 (left panel) and AZD2014 with AZD2281 (right panel) activates the RIPK1 Ser 166 phosphorylation in Clone A and SF-539 cells respectively.

  • 1/16

    Vistusertib purchased from MedChemExpress. Usage Cited in: Oncotarget. 2018 Sep 21;9(74):33995-34008. [Abstract]

    Customer Validation
     The treatment groups incorporating Selumetinib effectively blocks downstream p-ERK1/2 signaling, AZD2014 has a marked reduction in downstream mTORC1/2 effectors p-AKT, p-S6RP and p-4EBP1, and blockade of RICTOR.

  • 1/16

    Vistusertib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2017 Jun 8;8:15617. [Abstract]

    Customer Validation
     Immunoblot analysis of KRAS protein levels in parental (P) and resistant derivatives (R1 and R2) following 4 h treatment with the corresponding inhibitor AZD2014 (Vistusertib).

  • 1/16

    Vistusertib purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Feb 21;8(8):12775-12783. [Abstract]

    Customer Validation
     OSI-027, AZD-8055 and AZD-2014 almost completely block MHY1485-induced mTOR activation (p-mTOR/S6K1/Akt Ser473) in skin keratinocytes.

  • 1/16

    Vistusertib purchased from MedChemExpress. Usage Cited in: Patent. US20160089377A1.

    Customer Validation
     Western blot of cortical extracts from Cntnap2 mutant or wild-type mice treated with vehicle or various mTOR pathway inhibitors, showing staining for the presence of phosphorylated S6. Individual mice are tested, and are represented in the lanes as follows. Lane 1=Cntnap2+/− mouse 9-10 weeks old treated with vehicle as for AZD2014; Lane 2=Cntnap2+/− mouse 7.3 months old treated with Rapamycin; Lane 3=Cntnap2+/− mouse 6.3 months old treated with Torin 2; Lane 4=Cn

  • Vistusertib